2021
DOI: 10.3390/ijns7030058
|View full text |Cite
|
Sign up to set email alerts
|

Advanced Diagnostic System and Introduction of Newborn Screening of Adrenoleukodystrophy and Peroxisomal Disorders in Japan

Abstract: We established a diagnostic system for adrenoleukodystrophy (ALD) and peroxisomal disorders (PD) over 35 years ago in Japan, and have diagnosed 237 families with ALD and more than 100 cases of PD other than ALD using biochemical and molecular analyses. In particular, since the only treatment for the cerebral form of ALD is hematopoietic stem cell transplantation at an early stage of onset, we have developed a protocol for the rapid diagnosis of ALD that can provide the measurements of the levels of very-long-c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
13
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 23 publications
0
13
0
Order By: Relevance
“…In Japan, X-ALD diagnoses have long occurred through a streamlined diagnostic approach at a single referral center [ 51 ]. That system screened asymptomatic relatives of known X-ALD cases to facilitate presymptomatic diagnosis but ultimately relied on the identification of symptomatic individuals as a starting point [ 51 , 52 ]. In April 2021, a pilot study of NBS for X-ALD in Japan was initiated in which only results from babies with typical male-appearing external genitalia at birth were recorded [ 52 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In Japan, X-ALD diagnoses have long occurred through a streamlined diagnostic approach at a single referral center [ 51 ]. That system screened asymptomatic relatives of known X-ALD cases to facilitate presymptomatic diagnosis but ultimately relied on the identification of symptomatic individuals as a starting point [ 51 , 52 ]. In April 2021, a pilot study of NBS for X-ALD in Japan was initiated in which only results from babies with typical male-appearing external genitalia at birth were recorded [ 52 ].…”
Section: Discussionmentioning
confidence: 99%
“…That system screened asymptomatic relatives of known X-ALD cases to facilitate presymptomatic diagnosis but ultimately relied on the identification of symptomatic individuals as a starting point [ 51 , 52 ]. In April 2021, a pilot study of NBS for X-ALD in Japan was initiated in which only results from babies with typical male-appearing external genitalia at birth were recorded [ 52 ]. Although rare, this presents an interesting challenge in cases of atypically appearing external genitalia or gonadal dysgenesis, both of which can obscure identification of babies with a single X chromosome.…”
Section: Discussionmentioning
confidence: 99%
“…The previously established C26:0-LPC measurement in DBSs by negative mode LC-MS/MS methods has a satisfactory screening false positive rate, but it takes three minutes to process each specimen [ 27 , 28 , 29 ]. A positive mode LC-MS/MS method was reported with a runtime of two minutes per sample and features a low false positive rate [ 30 , 31 ]. The positive mode FIA-MS/MS method takes fewer than two minutes to process each specimen, but its false positive rate is of concern [ 2 , 23 , 24 ].…”
Section: Discussionmentioning
confidence: 99%
“…A 3 min, negative mode LC-MS/MS method, introduced in 2012, eliminated detection of these interferences altogether, which has dramatically led to no false positive identifications when a borderline cutoff is employed that triggers repeat DBS collection and testing [ 27 , 28 , 29 ]. Additional LC method optimizations yielded two-minute sample analyses using positive mode LC-MS/MS that maintained low false positive rates similar to New York’s second tier testing [ 30 , 31 ]. Here we report a FIA–MS/MS X-ALD screen using newborn DBSs that is adapted from the negative mode LC-MS/MS assay.…”
Section: Introductionmentioning
confidence: 99%
“…In some NBS programs, C26:0-LPC is used as the only screening marker, and those with abnormal C26:0-LPC levels were retested before confirmatory tests [ 14 , 15 ]. Others measured both C26:0-LPC and C24:0-LPC and referred those with positive screening results from either test [ 13 , 16 ]. The sequencing of the ABCD1 gene was deemed critical for the diagnosis of ALD [ 17 ] and is included by most NBS programs for confirmatory testing.…”
Section: Introductionmentioning
confidence: 99%